ID: ALA139501

Max Phase: Preclinical

Molecular Formula: C24H23N5O

Molecular Weight: 397.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN1C(=O)c2c(nn(Cc3ccccc3)c2-c2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12

Standard InChI:  InChI=1S/C24H23N5O/c1-27-23(30)20-21(17-11-6-3-7-12-17)28(15-16-9-4-2-5-10-16)26-22(20)29-19-14-8-13-18(19)25-24(27)29/h2-7,9-12,18-19H,8,13-15H2,1H3/t18-,19+/m1/s1

Standard InChI Key:  LABGENIBVXEMHK-MOPGFXCFSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 397.48

Molecular Weight (Monoisotopic): 397.1903

AlogP: 3.78

#Rotatable Bonds: 3

Polar Surface Area: 53.73

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 1.89

CX LogP: 4.49

CX LogD: 4.49

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.68

Np Likeness Score: -0.65

References

1. Xia Y, Chackalamannil S, Czarniecki M, Tsai H, Vaccaro H, Cleven R, Cook J, Fawzi A, Watkins R, Zhang H..  (1997)  Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.,  40  (26): [PMID:9435906] [10.1021/jm970495b]

Source

Source(1):

• Scientific Literature